Top Markets
#1 Akedo Akedo +128.53%
#2 TENDIES TENDIES +95.14%
#3 Threshold Network Threshold Network +43.87%
#4 Verus Coin Verus Coin +43.84%
#5 Mubarak Mubarak +28.64%
#6 Bitway Bitway +24.60%
#7 Palladium Network Palladium Network +22.70%
#8 Cash Cat Cash Cat +21.77%
#9 MultiversX MultiversX +18.70%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Classificação em ações #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Preço da ação
$8.16
Última sincronização: 2025-06-26
Valor de mercado
$234.57M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Regulus Therapeutics Inc. (RGLS)

Categoria

Healthcare
Lucros da Regulus Therapeutics Inc. (RGLS)
Lucros em Mar 2025 TTM: $-47.52M
De acordo com os últimos relatórios financeiros da Regulus Therapeutics Inc., os ganhos atuais da empresa são de $-47.52M. Em 2023, a empresa teve ganhos de $-30.04M, uma diminuição em relação a aos ganhos de 2022, que foram de $-28.32M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Regulus Therapeutics Inc. de 2010 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
2026 (TTM) $-47.52M 2.51%
2024 $-46.36M 54.34%
2023 $-30.04M 6.05%
2022 $-28.32M 1.85%
2021 $-27.81M 76.78%
2020 $-15.73M -15.39%
2019 $-18.59M -61.78%
2018 $-48.65M -32.53%
2017 $-72.10M -11.90%
2016 $-81.84M 46.76%
2015 $-55.77M -1.61%
2014 $-56.68M 203.24%
2013 $-18.69M 7.31%
2012 $-17.42M 135.51%
2011 $-7.40M -52.56%
2010 $-15.59M 0.00%
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -11,199.91%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -4,204.73%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 6,395.94%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 8,351.24%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH